Kornimate/medical-research-clean huggingface dataset:
prevent maternal mortality using mobile technology

Conditions: Post-Partum

Summary: black women who reside in a rural area are at highest risk for maternal morbidity and mortality due to a combination of social and structural causes. the postpartum period is the most critical yet most neglected phase for preventing suboptimal or fatal maternal health outcomes. the goal of this project is to use a mobile app to provide personalized support and improve the lives of women during the early postpartum period. the information the study team gathers will help educate women and all who support them about the need to seek postpartum care and the impact postpartum care can have on pregnancy-related complications. participation in this research requires taking part in a focus group discussion which will allow participants to share or the person that supports the participant's story and experience with postpartum complications and willingness to use and desired features of a postpartum mobile app.

black women in georgia have the highest risk for adverse maternal outcomes, with a staggering 66.6 deaths per 100,000 live births, compared to 18.1 for hispanic women and 43.2 for white women. in rural georgia, these statistics are more profound, with black women experiencing 126.7 deaths per 100,000 live births compared to 78.3 deaths for white women. these disparities have existed for centuries and have also widened significantly over the last several decades. the proposed research aims to increase the effectiveness of postpartum discharge education and improve rural black women's compliance with postpartum care recommendations by developing and testing a culturally-informed "mhealth intervention" entitled prevent maternal mortality using mobile technology (pm3).

Eligibility criteria:
inclusion criteria: * participants self -identify as female * participants must self-identify as african american/black * aged 18-45 years * can speak or read english * participants must be able to give consent. * own a smart phone * reside in or near albany, lagrange, or waynesboro (within a 40 mile radius) * be in third trimester or recently had a baby (≤4 weeks postpartum) * can be contacted by phone or email after hospital discharge. exclusion criteria: * women will be excluded if they have known unavailability to follow-up * an active severe mental health condition, or developmental disability precluding informed consent

Keywords: postpartum black mothers
decompression of pudendal and inferior cluneal nerves using robot-assisted laparoscopy for entrapment neuralgias : the x-deco study

Conditions: Pudendal Neuralgia

Summary: the objective of our study is to evaluate the efficacy of the laparoscopic robot-assited approach after 1 year of follow-up, on pain experience, and anxiety, depression, post-traumatic stress syndrome and quality of life.

pudendal and inferior cluneal neuralgias are responsible for chronic pelvic perineal pain. the compression of both of the nerves are thought to be associated in approximately 25% of the pudendal neuralgias. the failure of the isolated pudendal decompression led in the early 2000s to the identification of an entrapment syndrome of the posterior femoral cutaneous nerve and its inferior cluneal branche around the ischial tuberosity. this subsequent neuralgia affects the posterior part of the perineum, lower buttock, and the posterior part of the thigh, without any associated neuro-vegetative symptoms, unlike in pudendal neuralgia. in case of failure of the medical treatment, the open trans-gluteal decompression was proposed as a gold standard. however, this technique remains invasive and requires a long recovery. in a previous study, the investigators demonstrated the feasibility of double decompression via a minimally invasive robot-assisted laparoscopic approach, and described a 4-step technique.

Eligibility criteria:
inclusion criteria: * patients over 18 years old * patients presenting a pudendal and inferior cluneal entrapment neuralgia with 5 positive"nantes criteria", and failure of the medical treatment * patient having given consent after reading the information note exclusion criteria: * absence of any "nantes criteria", * patient non suitable for surgery/general anesthesia

Keywords: pudendal inferior cluneal robot surgery decompression neurolysis laparoscopy
lifespan integration for posttraumatic stress disorder from an auto accident

Conditions: Posttraumatic Stress Disorder

Summary: the purpose of this study is to evaluate if lifespan integration (li) therapy reduces posttraumatic stress symptoms following a motor vehicle accident (mva) trauma

studies estimate a substantial proportion of mva survivors, ranging from 9.4% to 59.9%, will develop ptsd following an accident (blanchard \& hickling, 2004). based on conservative estimates, past research, indicates that mva-related ptsd may affect 2.5 to 7 million persons in the united states (blanchard \& hickling). furthermore, two seminal epidemiological studies (kessler et al., 1995; norris, 1992) that focused on causes of adult ptsd identified mvas as the most frequent trauma resulting in ptsd. for these reasons, mva-resultant ptsd represents a significant public health problem that needs not only to be thoroughly understood, but addressed with successful mental health treatment options (beck \& coffey, 2007; blanchard \& hickling, 1997, 2004; bryant et al., 1998; taylor et al., 1999; taylor et al., 2001). although there is empirical literature on the treatment of ptsd following an mva, additional efficacious and rigorously conducted studies with statistical underpinnings are required to determine the results that can be expected from alternative models of care (beck \& coffey; blanchard \& hickling, 1997, 2004).

Eligibility criteria:
inclusion criteria: * involved in or witnessed a car accident at least 6 months ago. * ptsd or distress or impairment in important areas of functioning following the car accident exclusion criteria: * moderate or severe head injury * current mental health treatment for the mva-related problem * severe chronic pre-injury mental health problems

Keywords: posttraumatic stress disorder ptsd car accident auto accident lifespan integration
impact of standardized monitoring for detection of atrial fibrillation in ischemic stroke

Conditions: Stroke; Atrial Fibrillation

Summary: investigator-initiated prospective randomized multicentre study to uncover the true burden of paroxysmal atrial fibrillation in a representative population of acute stroke patients without known atrial fibrillation.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke or transitory ischemic attack (with clinical deficit on enrolment or mri detected acute brain lesion on admission) * age ≥ 18 years * written or oral informed consent * stroke unit admission within 72 hours after stroke onset * start of standardized prolonged ecg monitoring within 24 hours after admission to the stroke unit * willingness to take part in the planned follow up examinations exclusion criteria: * known atrial fibrillation * atrial fibrillation detected by ecg on admission * atrial fibrillation detected prior study enrollment on the stroke unit * life expectancy \< 1 year (before actual stroke) * life expectancy \< 1 month (after actual stroke) * indication for oral anticoagulation other than atrial fibrillation (e.g. mechanical heart valve) * severity level according national institute of health stroke scale (nihss) score \> 22 * participation in an interventional trial

Keywords: stroke atrial fibrillation ecg
syndecan-4 as a biomarker in patients with chagas disease

Conditions: Chagas Disease

Summary: the purpose of this study is to analyze the efficacy of syndecan-4 as a biomarker on the chagas disease prognosis. this analysis will be done through the correlation between the plasmatic levels of this molecule with functional and laboratory tests.

increased serum levels of syndecan-4 have been correlated to acute myocardial infarction and chronic heart failure, suggesting that this molecule can be an important biomarker in heart diseases. in spite of that, there are no studies that have investigated the role of this molecule in chronic chagasic cardiomyopathy yet. in this project, our objective is to demonstrate the potential role of syndecan-4 in the prognosis of chronic chagasic cardiomyopathy, seeking a better fitting of the treatment through the identification of patients with the worse prognosis. the patients included in the study must at first sign the written consent. they shall be accompanied in the specialized outpatient clinics for chagas disease - hospital são rafael - centro de biotecnologia e terapia celular. they will be submitted to several tests, including: * collection of blood samples for biochemical analysis; * electrocardiogram; * holter electrocardiogram; * echocardiogram; * treadmill test; * x-ray imaging; * magnetic resonance imaging; * evaluation of the quality of life through the application of questionnaires (sf 36 and the minnesota living with heart failure questionnaire).

Eligibility criteria:
inclusion criteria: * chagas disease diagnosis confirmed by 2 different serologies * diagnosis of chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction. exclusion criteria: * significant valve disease defined as aortic stenosis with a gradient of ve/ao \> 50 mmhg * mitral stenosis with a valve area inferior than 1,5 cm2 * superior or moderated aortic and/or mitral regurgitation * chronic use of immunosuppressive agents * dialysis treatment of terminal renal failure * fever on the last 48 hours or evidence of systemic infection in activity according to the definition of sepsis of the accp/sccm (american college os chest physicians/society of critical care medicine) * current abusive use of alcohol or illicit drugs (based on the dsm iv) * any other comorbidities that impact patient's survival within the next 2 years * liver disease in activity * continuous use of steroids as treatment for copd * hematologic, neoplastic or bone diseases * homeostasis disturbances * inflammatory diseases or chronic infectious diseases

Keywords: syndecan-4 chagas disease biomarkers
oldpain2go®: an exploratory (pre-feasibility) study.

Conditions: Pain, Chronic

Summary: research question: is there any evidence to suggest that the oldpain2go® intervention merits scientific investigation?

aims: 1. to collect data to: 1. give an indication of the potential effect size, of any effects, from the oldpain2go® intervention, in people with persistent low back pain. 2. to explore the eligibility criteria, recruitment methods and materials proposed here, for potential use in a future feasibility study, of the oldpain2go® intervention. 2. to compare demographic characteristics, medical history and outcome measure data of: 1. people for whom oldpain2go® is indicated (at the oldpain2go® screening session), with those for whom it is not, 2. people for whom the oldpain2go® intervention works, after one treatment, with those for whom it does not, and 3. people for whom the oldpain2go® intervention works, after one, or two, treatments, with those for whom it does not work after two treatments.

Eligibility criteria:
inclusion criteria: * currently suffering from persistent, non-specific, low back pain * aged over 18 years * for whom oldpain2go® is indicated as a treatment option after the standard clinical screening process for the oldpain2go® treatment exclusion criteria: * any red flags, * any causative (or potentially causative) structural abnormality, or pathology detected or suspected * any concurrent pathology, or condition that would limit options for physiotherapy treatment, * lack of (or any reason to doubt presence of) mental capacity to give informed consent

Keywords: oldpain2go® feasibility
clinical study in infants with rapidly progressive lysosomal acid lipase deficiency

Conditions: Lysosomal Acid Lipase Deficiency

Summary: this was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (lal-d). eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.

lysosomal acid lipase deficiency is a rare autosomal recessive lipid storage disorder that is caused by a marked decrease or complete absence of the lal enzyme, leading to the accumulation of lipids, predominately cholesteryl esters and triglycerides, in various tissues and cell types. in the liver, accumulation of lipids in hepatocytes and macrophages leads to hepatomegaly, fibrosis, cirrhosis, liver dysfunction, and hepatic failure. in the small intestine, lipid-laden macrophage accumulation in the lamina propria leads to profound malabsorption. lysosomal acid lipase deficiency presenting in infancy is an extremely rare form of the disease characterized by profound malabsorption, growth failure, and hepatic failure that is usually fatal within the first 6 months of life.

Eligibility criteria:
inclusion criteria: 1. participant's parent or legal guardian (if applicable) consent to participation in the study 2. confirmation of documented decreased lal activity relative to the normal range of the lab performing the assay or confirmation of lal-d diagnosis as determined by a sponsor-approved central laboratory 3. substantial clinical concerns, in the opinion of investigator and sponsor, of rapid disease progression requiring urgent medical intervention including, but not restricted to the following: * marked abdominal distension and hepatomegaly * failure to thrive * disturbance of coagulation * severe anemia * sibling with rapidly progressive course of lal-d exclusion criteria: 1. clinically important concurrent disease 2. participant was \> 8 months of age at the time of first dosing 3. participant received an investigational medicinal product other than sebelipase alfa within 14 days prior to the first dose of sebelipase alfa in this study 4. myeloablative preparation, or other systemic pre-transplant conditioning, for hematopoietic stem cell or liver transplantation 5. previous hematopoietic stem cell or liver transplant 6. known hypersensitivity to eggs

Keywords: lipa wolman disease wolman phenotype acid lipase deficiency acid cholesteryl hydrolase acid lipase disease deficiency, type 2 cholesteryl ester storage disease (cesd) cholesteryl ester hydrolase deficiency early onset lysosomal acid lipase deficiency (wolman disease) lal deficiency late onset lysosomal acid lipase deficiency (cesd) wolman disease (early onset lal deficiency) related disorders: non-alcoholic fatty liver disease (nafld) non-alcoholic steatohepatitis (nash) alcoholic liver disease cryptogenic cirrhosis niemann-pick disease (npd) type c chanarin dorfman syndrome
melphalan, thalidomide, and dexamethasone in treating patients with newly diagnosed, previously untreated primary systemic amyloidosis

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis. purpose: this phase ii trial is studying how well giving melphalan together with thalidomide and dexamethasone works in treating patients with primary systemic amyloidosis.

objectives: primary * determine the 2-year and overall progression-free survival of patients with newly diagnosed, previously untreated primary systemic (al) amyloidosis treated with risk-adapted melphalan followed by thalidomide and dexamethasone. secondary * determine plasma cell disease response in these patients at 3, 12, and 24 months after treatment with this regimen. * determine amyloid-related disease response in these patients at 12 and 24 months after treatment with this regimen. * determine the prognostic significance of immunoglobulin light-chain variable-region germline gene expression by al plasma cell clones in patients treated with this regimen. * determine whether there is molecular minimal residual disease at 12 and 24 months in patients achieving a complete hematologic response after treatment with this regimen. outline: patients are stratified according to the extent of amyloid-related disease (low-risk vs high-risk). * high-risk disease: patients receive 2 courses of low-dose melphalan iv, dexamethasone, and filgrastim (g-csf). after 3 months, patients receive thalidomide and dexamethasone if plasma cell disease persists. * low-risk disease: patients receive 1 course of high-dose melphalan iv and g-csf. patients then receive thalidomide and dexamethasone as in high-risk disease regimen. patients are followed at 3, 12, and 24 months. projected accrual: a total of 82 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of primary systemic (al) amyloidosis within the past 12 months * high- or low-risk disease, determined by the extent of systemic organ involvement with disease and patient age patient characteristics: age * 18 and over performance status * swog 0-3 life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified cardiovascular * no new york heart association class iii or iv congestive heart failure * no restrictive cardiomyopathy requiring oxygen * no myocardial infarction within the past 6 months * no symptomatic cardiac arrhythmia within the past 60 days other * no other active malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage i cancer in complete remission prior concurrent therapy: biologic therapy * not specified chemotherapy * no prior chemotherapy for al amyloidosis endocrine therapy * not specified radiotherapy * not specified surgery * not specified other * no other prior or concurrent therapy for al amyloidosis

Keywords: primary systemic amyloidosis
comparing the effect of physical therapy with oral appliance on temporomandibular disorder related myofascial pain

Conditions: Temporomandibular Disorder

Summary: the purpose of this study is to compare the effect of physical therapy (pt) program and oral appliance on patients with temporomandibular disorder (tmd)-related myofascial pain (mfp).

the details of each intervention are listed as following: * physical therapy program group (pt): manual myofascial release over craniomandibular system, chin-in exercise and self-care education * oral appliance group (splint): custom-made stabilization splint and self-care education

Eligibility criteria:
inclusion criteria: * (1) 20-65 years old female, (2) diagnosed as mfp subtype of tmd according to research diagnostic criteria for tmd (rdc/tmd), (3) pain duration over 3 month, (4) palpable taut band in masseter, (5) asymmetrical pain intensity, (6) subsided symptoms of joint inflammation. exclusion criteria: * (1) traumatic tmd from external impact force, (2) history of traumatic cervical injury, (3) presence of systemic disease, (4) fibromyalgia, (5) co-interventions for cervical problems or tmd during study period, (6) signs of psychosomatic illness, (7) unwilling to be randomized, (8) unable to wear the splint or received intraoral myofascial release, (9)pregnancy.

Keywords: temporomandibular joint disorder myofascial pain manual myofascial release physical therapy oral appliance
the effect of laughter yoga on the anxiety and stress levels of women in the postpartum period

Conditions: Laughter Yoga

Summary: this research is a randomized controlled study to evaluate the effect of laughter yoga on the anxiety and stress levels of postpartum women. randomization was provided in the sample included in the study, and it was divided into experimental and control groups. at the beginning of the study, the postpartum anxiety scale and the perceived stress scale were applied to women in both groups to determine their anxiety and stress levels. afterwards, 8 sessions of laughter yoga were applied to the experimental group for 4 weeks. no application was made to the control group. after 4 weeks, the postpartum anxiety scale and the perceived stress scale were administered to the women in both groups to re-determine their anxiety and stress levels.

this research is a randomized controlled study to evaluate the effect of laughter yoga on the anxiety and stress levels of postpartum women. at the beginning of the study, necessary ethics committee permission and institutional permissions were obtained. both of the researchers have a certificate of leadership in laughter yoga. as a result of the power analysis, it was determined that 128 women should be included in the study. considering that there may be losses, it was decided to include 160 women in the study. by providing randomization, 160 women who met the sampling criteria and volunteered to participate in the study were divided into two groups as 80 experimental and 80 control. at the beginning of the study, the postpartum anxiety scale and the perceived stress scale were applied to women in both groups to determine their anxiety and stress levels. afterwards, 8 sessions of laughter yoga were applied to the experimental group for 4 weeks, two sessions a week. no application was made to the control group. after 4 weeks, the postpartum anxiety scale and the perceived stress scale were administered to the women in both groups to re-determine their anxiety and stress levels. in the study, 7 women from the experimental group and 9 women from the control group were excluded for various reasons. the study was conducted with 73 experimental and 71 control groups. the process of making analyzes and writing the final report continues. this study is financially supported by atatürk university scientific research coordination unit. in addition, this study is carried out as a master's thesis accepted by atatürk university health sciences institute.

Eligibility criteria:
inclusion criteria: * be between the ages of 19-45 * giving birth by vaginal / caesarean section * 1 month after birth * having a healthy baby * not experiencing any complications during birth and postpartum * at least primary school graduate * not having a diagnosed psychiatric disease exclusion criteria: * having a medical condition (hypertension, wound complication, etc.) * not regularly attending laughter yoga sessions (for the experimental group) * applying another alternative method to reduce anxiety and stress in the postpartum period

Keywords: laughter yoga postpartum period anxiety stress nurse